Adare Pharma divests Adare Biome to dsm-firmenich
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Augnito’s AI comprehends all English accents with 99% accuracy
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated